-
1
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
-
2
-
-
22044453790
-
Erlotinib in lung cancer - molecular and clinical predictors of outcome
-
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, et al. (2005) Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
Zhu, C.Q.4
Kamel-Reid, S.5
-
3
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
Riely, G.J.4
Somwar, R.5
-
4
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
-
5
-
-
33749435816
-
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
-
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, et al. (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116: 2695-2706.
-
(2006)
J Clin Invest
, vol.116
, pp. 2695-2706
-
-
Engelman, J.A.1
Mukohara, T.2
Zejnullahu, K.3
Lifshits, E.4
Borras, A.M.5
-
6
-
-
36448963854
-
Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients
-
Lemos-Gonzalez Y, Paez de la Cadena M, Rodriguez-Berrocal FJ, Rodriguez-Pineiro AM, Pallas E, et al. (2007) Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol 28: 273-279.
-
(2007)
Tumour Biol
, vol.28
, pp. 273-279
-
-
Lemos-Gonzalez, Y.1
Paez de la Cadena, M.2
Rodriguez-Berrocal, F.J.3
Rodriguez-Pineiro, A.M.4
Pallas, E.5
-
7
-
-
33947322389
-
Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer
-
Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, et al. (2007) Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141: 464-469.
-
(2007)
Surgery
, vol.141
, pp. 464-469
-
-
Tzeng, C.W.1
Frolov, A.2
Frolova, N.3
Jhala, N.C.4
Howard, J.H.5
-
8
-
-
62449150719
-
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
-
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, et al. (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27: 1268-1274.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1268-1274
-
-
van den Bent, M.J.1
Brandes, A.A.2
Rampling, R.3
Kouwenhoven, M.C.4
Kros, J.M.5
-
9
-
-
3843116718
-
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
-
Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, et al. (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91: 208-212.
-
(2004)
Br J Cancer
, vol.91
, pp. 208-212
-
-
Parra, H.S.1
Cavina, R.2
Latteri, F.3
Zucali, P.A.4
Campagnoli, E.5
-
10
-
-
20444498630
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
-
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 643-655
-
-
Cappuzzo, F.1
Hirsch, F.R.2
Rossi, E.3
Bartolini, S.4
Ceresoli, G.L.5
-
11
-
-
0033796072
-
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain
-
Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, et al. (2000) Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 20: 7735-7750.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 7735-7750
-
-
Fiorentino, L.1
Pertica, C.2
Fiorini, M.3
Talora, C.4
Crescenzi, M.5
-
12
-
-
0035700605
-
Mig-6 is a negative regulator of the epidermal growth factor receptor signal
-
Hackel PO, Gishizky M, Ullrich A, (2001) Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem 382: 1649-1662.
-
(2001)
Biol Chem
, vol.382
, pp. 1649-1662
-
-
Hackel, P.O.1
Gishizky, M.2
Ullrich, A.3
-
13
-
-
0038037236
-
Feedback inhibition by RALT controls signal output by the ErbB network
-
Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, et al. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22: 4221-4234.
-
(2003)
Oncogene
, vol.22
, pp. 4221-4234
-
-
Anastasi, S.1
Fiorentino, L.2
Fiorini, M.3
Fraioli, R.4
Sala, G.5
-
14
-
-
36749011864
-
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
-
Zhang X, Pickin KA, Bose R, Jura N, Cole PA, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741-744.
-
(2007)
Nature
, vol.450
, pp. 741-744
-
-
Zhang, X.1
Pickin, K.A.2
Bose, R.3
Jura, N.4
Cole, P.A.5
-
15
-
-
33646588346
-
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation
-
Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, et al. (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12: 568-573.
-
(2006)
Nat Med
, vol.12
, pp. 568-573
-
-
Ferby, I.1
Reschke, M.2
Kudlacek, O.3
Knyazev, P.4
Pante, G.5
-
16
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
-
17
-
-
34250898667
-
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
-
Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, et al. (2007) Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67: 5779-5788.
-
(2007)
Cancer Res
, vol.67
, pp. 5779-5788
-
-
Yamasaki, F.1
Johansen, M.J.2
Zhang, D.3
Krishnamurthy, S.4
Felix, E.5
-
18
-
-
0037136702
-
Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control
-
Fiorini M, Ballaro C, Sala G, Falcone G, Alema S, et al. (2002) Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 21: 6530-6539.
-
(2002)
Oncogene
, vol.21
, pp. 6530-6539
-
-
Fiorini, M.1
Ballaro, C.2
Sala, G.3
Falcone, G.4
Alema, S.5
-
19
-
-
0035398631
-
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
-
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3267-3279
-
-
Hidalgo, M.1
Siu, L.L.2
Nemunaitis, J.3
Rizzo, J.4
Hammond, L.A.5
-
20
-
-
69349087756
-
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
-
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, et al. (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5060-5072
-
-
Adam, L.1
Zhong, M.2
Choi, W.3
Qi, W.4
Nicoloso, M.5
-
21
-
-
34147160767
-
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
-
Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, et al. (2007) Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther 6: 1079-1088.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1079-1088
-
-
Jimeno, A.1
Rubio-Viqueira, B.2
Amador, M.L.3
Grunwald, V.4
Maitra, A.5
-
22
-
-
42349093818
-
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
-
Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, et al. (2008) Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68: 2841-2849.
-
(2008)
Cancer Res
, vol.68
, pp. 2841-2849
-
-
Jimeno, A.1
Tan, A.C.2
Coffa, J.3
Rajeshkumar, N.V.4
Kulesza, P.5
-
23
-
-
58149382070
-
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy
-
Harsha HC, Jimeno A, Molina H, Mihalas AB, Goggins MG, et al. (2008) Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7: 4651-4658.
-
(2008)
J Proteome Res
, vol.7
, pp. 4651-4658
-
-
Harsha, H.C.1
Jimeno, A.2
Molina, H.3
Mihalas, A.B.4
Goggins, M.G.5
-
24
-
-
57049132745
-
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
-
Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD, (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843-854.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 843-854
-
-
Thomson, S.1
Petti, F.2
Sujka-Kwok, I.3
Epstein, D.4
Haley, J.D.5
-
25
-
-
79953745096
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
-
Zhang S, Huang WC, Li P, Guo H, Poh SB, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med.
-
(2011)
Nat Med
-
-
Zhang, S.1
Huang, W.C.2
Li, P.3
Guo, H.4
Poh, S.B.5
-
26
-
-
77951785332
-
A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
-
Frosi Y, Anastasi S, Ballaro C, Varsano G, Castellani L, et al. (2010) A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189: 557-571.
-
(2010)
J Cell Biol
, vol.189
, pp. 557-571
-
-
Frosi, Y.1
Anastasi, S.2
Ballaro, C.3
Varsano, G.4
Castellani, L.5
-
27
-
-
77951061655
-
Mig-6 controls EGFR trafficking and suppresses gliomagenesis
-
Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, et al. (2010) Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 107: 6912-6917.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 6912-6917
-
-
Ying, H.1
Zheng, H.2
Scott, K.3
Wiedemeyer, R.4
Yan, H.5
-
28
-
-
68349136921
-
Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction
-
Descot A, Hoffmann R, Shaposhnikov D, Reschke M, Ullrich A, et al. (2009) Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol Cell 35: 291-304.
-
(2009)
Mol Cell
, vol.35
, pp. 291-304
-
-
Descot, A.1
Hoffmann, R.2
Shaposhnikov, D.3
Reschke, M.4
Ullrich, A.5
-
29
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
-
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
-
30
-
-
63449122814
-
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells
-
Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, et al. (2009) Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15: 1585-1592.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1585-1592
-
-
Benavente, S.1
Huang, S.2
Armstrong, E.A.3
Chi, A.4
Hsu, K.T.5
-
31
-
-
79958787979
-
Adenylate kinase 3 sensitizes cells to cigarette smoke condensate vapor induced cisplatin resistance
-
Chang X, Ravi R, Pham V, Bedi A, Chatterjee A, et al. (2011) Adenylate kinase 3 sensitizes cells to cigarette smoke condensate vapor induced cisplatin resistance. PLoS One 6: e20806.
-
(2011)
PLoS One
, vol.6
-
-
Chang, X.1
Ravi, R.2
Pham, V.3
Bedi, A.4
Chatterjee, A.5
-
32
-
-
34249810645
-
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
-
Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, et al. (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-2896.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2890-2896
-
-
Massarelli, E.1
Varella-Garcia, M.2
Tang, X.3
Xavier, A.C.4
Ozburn, N.C.5
-
33
-
-
8744287732
-
Pathology of pulmonary vasculitis
-
Travis WD, (2004) Pathology of pulmonary vasculitis. Semin Respir Crit Care Med 25: 475-482.
-
(2004)
Semin Respir Crit Care Med
, vol.25
, pp. 475-482
-
-
Travis, W.D.1
-
34
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
|